This report describes and explains the coronavirus (COVID-19) current therapy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global coronavirus (COVID-19) current therapy market reached a value of nearly $9.36 billion in 2024. The market is expected to grow from $9.36 billion in 2024 to $541.44 million in 2029 at a rate of -43.46%. The market is then expected to grow at a CAGR of -100% from 2029.
Growth in the historic period resulted from the new COVID-19 strains and impact of COVID-19 pandemic, increasing adoption of telemedicine, expanding clinical trials and rising vaccination programs. Factors that negatively affected growth in the historic period were regulatory hurdles.
Going forward, the rising prevalence of chronic diseases, increasing aging population, increase in healthcare expenditure and favorable government initiatives will drive the growth. Factor that could hinder the growth of the coronavirus (COVID-19) current therapy market in the future include high cost of therapies and decline in demand for COVID-19 therapeutics.
The global coronavirus (COVID-19) current therapy market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 40.4% of the total market in 2023. Gilead Sciences, Inc. was the largest competitor with a 18.61% share of the market, followed by Merck & Co. with 12.17%, Regeneron Pharmaceuticals, Inc. with 5.27%, F. Hoffmann-La Roche AG. with 0.96%, Ipca Laboratories Limited. with 0.66%, Zydus Group. with 0.65%, Sun Pharmaceutical Industries Limited with 0.61%, AbbVie Inc. with 0.52%, Pfizer Inc. with 0.49% and Glenmark Pharmaceuticals Limited with 0.46%.
The coronavirus (COVID-19) current therapy market is segmented by drug type into antivirals, Mabs, corticosteroid, supplements, antimalarial, interferons and interleukin inhibitors, other anti-infections and others. The antiviral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug type, accounting for 29.54% or $2.76 billion of the total in 2024. Going forward, the mabs segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by drug type, at a CAGR of -40.94% during 2024-2029.
The coronavirus (COVID-19) current therapy market is segmented by route of administration into oral and intravenous. The oral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by route of administration, accounting for 64.28% or $6.02 billion of the total in 2024. Going forward, the intravenous segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by route of administration, at a CAGR of -40.16% during 2024-2029.
The COVID-19 current therapy market is segmented by end-user into hospitals, clinics, home care and other end-users. The hospitals market was the largest segment of the COVID-19 current therapy market segmented by end-user, accounting for 57.49% or $5.38 billion of the total in 2024. Going forward, the home care segment is expected to be the fastest growing segment in the COVID-19 current therapy market segmented by end-user, at a CAGR of -42.36% during 2024-2029.
North America was the largest region in the coronavirus (COVID-19) current therapy market, accounting for 54.44% or $5.09 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the coronavirus (COVID-19) current therapy market will be North America and Western Europe where growth will be at CAGRs of -40.16% and -42.83% respectively. These will be followed by Asia-Pacific and Eastern Europe where the markets are expected to grow at CAGRs of -50.58% and -53.28% respectively.
The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by drug type will arise in the supplements segment, which will gain $-80.63 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy market segmented by route of administration will arise in the intravenous segment, which will gain $-3,089.5 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by end-user will arise in the other end-users segment, which will gain $-827.84 million of global annual sales by 2029. The coronavirus (COVID-19) current therapy market size will gain the most in Indonesia at $-32.3 million.
Market-trend-based strategies for the COVID-19 current therapy market include focus on strategic investments to accelerate the development of effective therapies and expand clinical research, focus on developing antiviral drugs and focus on developing innovative digital platforms.
Player-adopted strategies in the coronavirus (COVID-19) current therapy market include focus on expanding its business capabilities through new clinical trials and focuses on enhancing its operational capabilities through strategic partnerships and drug approvals.
To take advantage of the opportunities, the analyst recommends the COVID-19 current therapy companies to focus on strategic investments and R&D for growth, focus on developing targeted antiviral therapies, focus on innovating digital platforms for enhanced patient care, focus on the "others" anti-infections segment, focus on the oral segment, expand in emerging markets, focus on expanding distribution channels to enhance accessibility, focus on strategic pricing to maximize market penetration, focus on building trust and credibility for COVID-19 therapy companies, focus on strategic partnerships with healthcare providers and insurers to boost product adoption and focus on the home care market.
The global coronavirus (COVID-19) current therapy market reached a value of nearly $9.36 billion in 2024. The market is expected to grow from $9.36 billion in 2024 to $541.44 million in 2029 at a rate of -43.46%. The market is then expected to grow at a CAGR of -100% from 2029.
Growth in the historic period resulted from the new COVID-19 strains and impact of COVID-19 pandemic, increasing adoption of telemedicine, expanding clinical trials and rising vaccination programs. Factors that negatively affected growth in the historic period were regulatory hurdles.
Going forward, the rising prevalence of chronic diseases, increasing aging population, increase in healthcare expenditure and favorable government initiatives will drive the growth. Factor that could hinder the growth of the coronavirus (COVID-19) current therapy market in the future include high cost of therapies and decline in demand for COVID-19 therapeutics.
The global coronavirus (COVID-19) current therapy market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 40.4% of the total market in 2023. Gilead Sciences, Inc. was the largest competitor with a 18.61% share of the market, followed by Merck & Co. with 12.17%, Regeneron Pharmaceuticals, Inc. with 5.27%, F. Hoffmann-La Roche AG. with 0.96%, Ipca Laboratories Limited. with 0.66%, Zydus Group. with 0.65%, Sun Pharmaceutical Industries Limited with 0.61%, AbbVie Inc. with 0.52%, Pfizer Inc. with 0.49% and Glenmark Pharmaceuticals Limited with 0.46%.
The coronavirus (COVID-19) current therapy market is segmented by drug type into antivirals, Mabs, corticosteroid, supplements, antimalarial, interferons and interleukin inhibitors, other anti-infections and others. The antiviral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug type, accounting for 29.54% or $2.76 billion of the total in 2024. Going forward, the mabs segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by drug type, at a CAGR of -40.94% during 2024-2029.
The coronavirus (COVID-19) current therapy market is segmented by route of administration into oral and intravenous. The oral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by route of administration, accounting for 64.28% or $6.02 billion of the total in 2024. Going forward, the intravenous segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by route of administration, at a CAGR of -40.16% during 2024-2029.
The COVID-19 current therapy market is segmented by end-user into hospitals, clinics, home care and other end-users. The hospitals market was the largest segment of the COVID-19 current therapy market segmented by end-user, accounting for 57.49% or $5.38 billion of the total in 2024. Going forward, the home care segment is expected to be the fastest growing segment in the COVID-19 current therapy market segmented by end-user, at a CAGR of -42.36% during 2024-2029.
North America was the largest region in the coronavirus (COVID-19) current therapy market, accounting for 54.44% or $5.09 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the coronavirus (COVID-19) current therapy market will be North America and Western Europe where growth will be at CAGRs of -40.16% and -42.83% respectively. These will be followed by Asia-Pacific and Eastern Europe where the markets are expected to grow at CAGRs of -50.58% and -53.28% respectively.
The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by drug type will arise in the supplements segment, which will gain $-80.63 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy market segmented by route of administration will arise in the intravenous segment, which will gain $-3,089.5 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by end-user will arise in the other end-users segment, which will gain $-827.84 million of global annual sales by 2029. The coronavirus (COVID-19) current therapy market size will gain the most in Indonesia at $-32.3 million.
Market-trend-based strategies for the COVID-19 current therapy market include focus on strategic investments to accelerate the development of effective therapies and expand clinical research, focus on developing antiviral drugs and focus on developing innovative digital platforms.
Player-adopted strategies in the coronavirus (COVID-19) current therapy market include focus on expanding its business capabilities through new clinical trials and focuses on enhancing its operational capabilities through strategic partnerships and drug approvals.
To take advantage of the opportunities, the analyst recommends the COVID-19 current therapy companies to focus on strategic investments and R&D for growth, focus on developing targeted antiviral therapies, focus on innovating digital platforms for enhanced patient care, focus on the "others" anti-infections segment, focus on the oral segment, expand in emerging markets, focus on expanding distribution channels to enhance accessibility, focus on strategic pricing to maximize market penetration, focus on building trust and credibility for COVID-19 therapy companies, focus on strategic partnerships with healthcare providers and insurers to boost product adoption and focus on the home care market.
Major Market Trends
- Strategic Investments Driving COVID-19 Therapy Market Growth
- Advancements in Antiviral Drug Development for COVID-19 Treatment
- Digital Solutions Transforming Healthcare Accessibility
Key Mergers and Acquisitions
- GSK Acquires CureVac
- FSII-Pardes Biosciences Merger Aims to Enhance COVID-19 Antiviral Therapy Capabilities
- Opportunities and Strategies
- Global Coronavirus (COVID-19) Current Therapy Market in 2029 - Growth Strategies
- Market Trend Based Strategies
- Competitor Strategies
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Coronavirus (COVID-19) Current Therapy Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Coronavirus (COVID-19) Current Therapy Market Segmentation
11 Coronavirus (COVID-19) Current Therapy Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Other Major and Innovative Companies
23 Key Mergers and Acquisitions
24 Opportunities and Strategies
25 COVID-19 Current Therapy Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Coronavirus (COVID-19) Current Therapy Global Market Opportunities and Strategies to 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for coronavirus (COVID-19) current therapy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The coronavirus (COVID-19) current therapy market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider coronavirus (COVID-19) current therapy market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug type, by route of administration and by end-user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - the report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the COVID-19 current therapy market.
- Global Market Size and Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug type, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for coronavirus (COVID-19) current therapy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) by Drug Type: Antivirals; Monoclonal Antibodies (Mabs); Corticosteroid; Supplements; Antimalarial; Interferons and Interleukin Inhibitors; Other Anti Infections; Others2) by Route of Administration: Oral; Intravenous
3) by End User: Hospitals; Clinics; Home Care; Other End Users
Key Companies Mentioned: Gilead Sciences, Inc.; Merck & Co; Regeneron Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Ipca Laboratories Limited
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; coronavirus (COVID-19) current therapy indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
Some of the major companies featured in this Coronavirus (COVID-19) Current Therapy market report include:- Gilead Sciences, Inc.
- Merck & Co
- Regeneron Pharmaceuticals, Inc
- F. Hoffmann-La Roche AG
- Ipca Laboratories Limited
- Zydus Group
- Sun Pharmaceutical Industries Limited
- AbbVie Inc
- Pfizer Inc
- Glenmark Pharmaceuticals Limited
- Lupin Limited
- Cipla Limited
- Bajaj Healthcare
- CSPC Pharmaceutical Group
- 111 Inc
- Brii Bio
- Pharmaceutical Commercial Group
- Sinopharm Holding Co
- Advaccine Biopharmaceutical
- Shionogi & Co., Ltd
- Takeda Pharmaceutical Company
- Mylab Discovery Solutions
- Kalbe Farma
- He Qi Group Foundation
- Beijing Jinwofu Bioengineering Technology
- Zhejiang Orient Gene Biotech Co. Ltd
- Transasia Bio Medicals
- Vanguard Diagnostics
- HLL Lifecare Limited
- Voxtur Bio Ltd
- LAB-CARE Diagnostics
- CPC Diagnostics
- Seegene
- SD Biosensor
- Getein Biotech
- Hangzhou Biotest Biotech
- AmonMed Biotechnology
- Beijing Tigsun Diagnostics
- Hunan Lituo Biotechnology
- Vivacheck Lab
- Fujirebio
- Sysmex Corporation
- Atomo Diagnostics
- Motologic
- Siemens Healthcare Pte Ltd
- Senova
- LetsGetChecked
- Omega Diagnostics
- Abingdon Health
- Babylon
- Novacyt Group
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline (GSK)
- Novartis AG
- Sanofi
- Amarin Corporation
- Roivant Sciences
- ViroBlock
- Zentiva
- AbbVie Inc.
- Pfizer Inc.
- Adagio Therapeutics
- INOVIO Pharmaceuticals
- ImmunoScience
- Abbott Laboratories
- Mylan
- Eli Lilly and Company
- Sorrento Therapeutics, Inc.
- Ridgeback Biotherapeutics
- Veru Inc
- NRx Pharmaceuticals Inc
- Thermo Fisher Scientific
- CytoDyn
- Atea Pharmaceuticals Inc
- Alexion Pharmaceuticals
- Johnson & Johnson Ltd
- Genentech Inc.
- Moderna
- Canary Health Technologies
- BioMedomics
- CTK Biotech
- Teva Pharmaceutical Industries Ltd
- Abdi İbrahim Pharmaceuticals
- Julphar
- G42 Healthcare
- SaudiVax
- CapeBio
- Astel Diagnostics
